TON - November 2016, Vol 9, No 6

A novel compound called CPX-351 that combines 2 older drugs (cytarabine and daunorubicin) in a new drug-delivery platform improved survival among older patients with newly diagnosed, high-risk (secondary) acute myeloid leukemia (AML). Read More ›

Stomatitis is a dose-limiting toxicity associated with the use of mammalian target of rapamycin (mTOR) inhibitors, but new treatments can improve quality of life for patients suffering from this often debilitating condition. Read More ›

As a result of the FDA approval of the DigniCap (Dignitana) system last year, and the growing evidence that scalp cooling is effective in preventing chemotherapy-induced alopecia, the practice is steadily becoming more widespread in the United States. Read More ›

  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Enzalutamide Superior to Bicalutamide in Patients with Prostate Cancer
Read More ›

If you cannot get your patients with lung cancer to stop smoking, at least encourage them to exercise. Read More ›

Noteworthy Numbers: Pancreatic Cancer
With national and international organizations recognizing November as Pancreatic Cancer Awareness Month and November 13 as World Pancreatic Cancer Day, there will be countless opportunities to show support and help raise awareness of this disease. Presented here are a few statistics about this deadly form of cancer. Read More ›

Page 3 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: